Iwatsubo Takeshi, Sperling Reisa A, Algeciras-Schimnich Alicia, Arai Hidenori, Barron Anna M, Benzinger Tammie L S, Carrillo Maria C, Chen Christopher, Choi Seong Hye, Fontana Igor C, Graff-Radford Jonathan, Grill Joshua D, Heidebrink Judith, Hu Chaur-Jong, Ihara Ryoko, Ikeuchi Takeshi, Iwata Atsushi, Ip Fanny C F, Fitri Fasihah Irfani, Jack Clifford R, Jeong Jee Hyang, Jia Jianping, Kandiah Nagaendran, Kim SangYun, Kowa Hisatomo, La Joie Renaud, Niimi Yoshiki, Noritake Ryoji, Okonkwo Ozioma C, Palmqvist Sebastian, Rafii Michael S, Raman Rema, Shen Yong, Simuni Tanya, Snyder Heather M, Sriwannopas Orapitchaya, Stoeckel Luke E, van der Flier Wiesje M, Wang Huali, Wilcock Donna M, Zetterberg Henrik, Zhou Jin, Mahinrad Simin, Sexton Claire E
Department of Neuropathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Alzheimers Dement. 2025 Aug;21(8):e70536. doi: 10.1002/alz.70536.
The landscape of Alzheimer's disease (AD) and related dementias (ADRD) diagnosis is evolving rapidly, driven by advances in disease understanding, biomarker tools, and disease-modifying therapies. Modern diagnostic approaches emphasize biological precision, early detection, and dynamic frameworks that adapt to treatment-induced changes in disease biology. These frameworks enable opportunities for personalized interventions-encompassing pharmacological and non-pharmacological strategies-and for enhanced clinical trial design. However, implementing these advancements globally is influenced by diverse cultural, infrastructural, and regulatory factors. The 2024 Alzheimer's Association International Conference Advancements: Modernizing Diagnosis, held in Japan, provided a unique platform to explore these global dynamics, particularly from an Asian perspective. This article highlights key discussions from the conference, exploring the role of biomarker-based diagnostic frameworks in shaping the future of AD/ADRD research, diagnosis, and treatment. We highlight regional challenges and successes and emphasize ethical considerations and practical strategies needed to ensure equitable access to diagnostic and therapeutic innovations. HIGHLIGHTS: Advances in biomarkers are reshaping Alzheimer's disease diagnosis and treatment. Modern diagnostic frameworks highlight biological precision, early detection, and dynamic frameworks. The 2024 Alzheimer's Association International Conference Advancements: Modernizing Diagnosis explored challenges and opportunities in global biomarker implementation. The conference explored geographic-specific impacts, focusing on Asia.
在对疾病的认识、生物标志物工具和疾病修饰疗法取得进展的推动下，阿尔茨海默病（AD）及相关痴呆症（ADRD）的诊断格局正在迅速演变。现代诊断方法强调生物学精准性、早期检测以及适应疾病生物学中治疗引起变化的动态框架。这些框架为个性化干预（包括药物和非药物策略）以及改进临床试验设计提供了机会。然而，在全球范围内实施这些进展受到多种文化、基础设施和监管因素的影响。2024年在日本举行的阿尔茨海默病协会国际会议“进展：诊断现代化”提供了一个独特的平台来探讨这些全球动态，特别是从亚洲视角。本文重点介绍了会议的关键讨论内容，探讨基于生物标志物的诊断框架在塑造AD/ADRD研究、诊断和治疗未来方面的作用。我们强调了区域挑战与成功经验，并强调了确保公平获得诊断和治疗创新所需的伦理考量和实际策略。要点：生物标志物的进展正在重塑阿尔茨海默病的诊断和治疗。现代诊断框架强调生物学精准性、早期检测和动态框架。2024年阿尔茨海默病协会国际会议“进展：诊断现代化”探讨了全球生物标志物实施中的挑战与机遇。会议探讨了特定地区的影响，重点关注亚洲。
